408 related articles for article (PubMed ID: 31404620)
41. Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials.
Dryden M; Kantecki M; Yan JL; Stone GG; Leister-Tebbe H; Wilcox M
J Glob Antimicrob Resist; 2022 Mar; 28():108-114. PubMed ID: 34922058
[TBL] [Abstract][Full Text] [Related]
42. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
43. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H
J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326
[TBL] [Abstract][Full Text] [Related]
44. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients.
Lin JC; Aung G; Thomas A; Jahng M; Johns S; Fierer J
J Infect Chemother; 2013 Feb; 19(1):42-9. PubMed ID: 22797874
[TBL] [Abstract][Full Text] [Related]
45. Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Taboada M; Melnick D; Iaconis JP; Sun F; Zhong NS; File TM; Llorens L; Friedland HD; Wilson D
J Antimicrob Chemother; 2016 Apr; 71(4):862-70. PubMed ID: 26702925
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
Sotgiu G; Aliberti S; Gramegna A; Mantero M; Di Pasquale M; Trogu F; Saderi L; Blasi F
Respir Res; 2018 Oct; 19(1):205. PubMed ID: 30352588
[TBL] [Abstract][Full Text] [Related]
47. Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients.
Pasquale TR; Tan MJ; Trienski TL; File TM
J Chemother; 2015 Feb; 27(1):29-34. PubMed ID: 24621164
[TBL] [Abstract][Full Text] [Related]
48. In vivo efficacy of ceftaroline fosamil in a methicillin-resistant panton-valentine leukocidin-producing Staphylococcus aureus rabbit pneumonia model.
Croisier-Bertin D; Hayez D; Da Silva S; Labrousse D; Biek D; Badiou C; Dumitrescu O; Guerard P; Charles PE; Piroth L; Lina G; Vandenesch F; Chavanet P
Antimicrob Agents Chemother; 2014; 58(4):1855-61. PubMed ID: 24395236
[TBL] [Abstract][Full Text] [Related]
49. Off-label use of ceftaroline fosamil: A systematic review.
Pani A; Colombo F; Agnelli F; Frantellizzi V; Baratta F; Pastori D; Scaglione F
Int J Antimicrob Agents; 2019 Nov; 54(5):562-571. PubMed ID: 31279152
[TBL] [Abstract][Full Text] [Related]
50. Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia.
Riccobene TA; Khariton T; Knebel W; Das S; Li J; Jandourek A; Carrothers TJ; Bradley JS
J Clin Pharmacol; 2017 Mar; 57(3):345-355. PubMed ID: 27510635
[TBL] [Abstract][Full Text] [Related]
51. Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE.
Carreno JJ; Lodise TP
Infect Dis Ther; 2014 Dec; 3(2):123-32. PubMed ID: 25193094
[TBL] [Abstract][Full Text] [Related]
52. Ceftaroline.
Soriano A
Rev Esp Quimioter; 2021 Sep; 34 Suppl 1(Suppl1):29-31. PubMed ID: 34598420
[TBL] [Abstract][Full Text] [Related]
53. Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia.
Maselli DJ; Fernandez JF; Whong CY; Echevarria K; Nambiar AM; Anzueto A; Restrepo MI
Infect Drug Resist; 2012; 5():43-51. PubMed ID: 22355258
[TBL] [Abstract][Full Text] [Related]
54. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain.
Bassetti M; Russo A; Cilloniz C; Giacobbe DR; Vena A; Amaro R; Graziano E; Soriano A; Torres A
Int J Antimicrob Agents; 2020 Apr; 55(4):105921. PubMed ID: 32061999
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017-2019.
Utt E; Kantecki M; Cabezas-Camarero G; Esposito S
J Glob Antimicrob Resist; 2023 Jun; 33():360-367. PubMed ID: 37187440
[TBL] [Abstract][Full Text] [Related]
56. Comparison of the in vivo efficacy of ceftaroline fosamil, vancomycin and daptomycin in a murine model of methicillin-resistant Staphylococcus aureus bacteraemia.
García P; Moscoso M; Fernández MC; Fuentes-Valverde V; Pérez A; Bou G
Int J Antimicrob Agents; 2023 Jul; 62(1):106836. PubMed ID: 37150362
[TBL] [Abstract][Full Text] [Related]
57. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
58. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency.
Maggiore C; Pasquale T; Cole P; Friedland HD
Expert Rev Clin Pharmacol; 2015 Jan; 8(1):141-53. PubMed ID: 25467425
[TBL] [Abstract][Full Text] [Related]
59. Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Farrell DJ; Flamm RK; Jones RN; Sader HS
Diagn Microbiol Infect Dis; 2013 Jan; 75(1):86-8. PubMed ID: 23146404
[TBL] [Abstract][Full Text] [Related]
60. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
